Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Charles A. Herzog, Richard W. Asinger, Alan K. Berger, David M. Charytan, Javier Díez, Robert G. Hart, Kai Uwe Eckardt, Bertram L. Kasiske, Peter A. McCullough, Rod S. Passman, Stephanie S. Deloach, Patrick H. Pun, Eberhard Ritz

Research output: Contribution to journalArticlepeer-review

698 Scopus citations


Cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). CKD is associated with specific risk factors. Emerging evidence indicates that the pathology and manifestation of CVD differ in the presence of CKD. During a clinical update conference convened by the Kidney Disease: Improving Global Outcomes (KDIGO), an international group of experts defined the current state of knowledge and the implications for patient care in important topic areas, including coronary artery disease and myocardial infarction, congestive heart failure, cerebrovascular disease, atrial fibrillation, peripheral arterial disease, and sudden cardiac death. Although optimal strategies for prevention, diagnosis, and management of these complications likely should be modified in the presence of CKD, the evidence base for decision making is limited. Trials targeting CVD in patients with CKD have a large potential to improve outcomes.

Original languageEnglish (US)
Pages (from-to)572-586
Number of pages15
JournalKidney international
Issue number6
StatePublished - Sep 2 2011

Bibliographical note

Funding Information:
PHP has received research funding from Satellite Health Care. BLK has received research funding from Bristol-Myers Squibb and Genzyme and is a paid advisor for Litholink (Lab Corp). RGH has received research consulting fees from Boehringer Ingleheim. RWA is a paid advisor for Atritech. RSP receives research support, speaker's fees, and consulting fees from Medtronic. K-UE has received lecture or consulting fees from Amgen, Bayer, Genzyme and GSK, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis. CAH has received research support from Amgen and Johnson & Johnson and honoraria from UpToDate, is a consultant for Amgen, CorMedix, Abbott Labs, FibroGen, Affymax, Fresenius, and Merck, and has equity interest in Cambridge Heart, Merck, Boston Scientific, and J&J. All other authors declared no competing interests. This conference was sponsored by KDIGO and was partially supported by unrestricted educational grants from Novartis, Takeda, and Abbott.


  • atrial fibrillation
  • heart failure
  • myocardial infarction
  • peripheral arterial disease
  • stroke
  • sudden death


Dive into the research topics of 'Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)'. Together they form a unique fingerprint.

Cite this